Acute hepatitis A is a major public health problem in developed countries, and because a large proportion of patients with acute hepatitis A do not have any identifiable risk factors, current practice of targeting the high-risk groups for vaccination against hepatitis A virus (HAV) is unlikely to ha
Economic models of hepatitis a virus immunization
β Scribed by Martin Meltzer; Mark L. Messonnier
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 39 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A search was carried out for economic evaluations of hepatitis B (HBV) vaccination, published between 1994 and 2000. The results of these studies are discussed according to the level of HBV endemicity. The great majority of these evaluations were carried out for industrialized countries
To investigate the antibody titer necessary to prevent hepatitis A virus infection, either 15 or 7.5 mg/kg of immune serum globulin was injected into 10 antihepatitis A virus negative volunteers and their serum antihepatitis A virus titers were observed for 28 wk. In addition, antibody titers were o
## Abstract Two hundred one immune serum globulin (ISG) lots manufactured in the US between 1967 and 1977 were tested for antibodies to the hepatitis A virus (antiβHAV) by a competitiveβinhibition radioimmunoassay (RIA); a lesser number were also tested by immune adherence hemagglutination (IAHA).